Potential biomarkers for early detection of acute graft-versus-host disease

Warning

This publication doesn't include Faculty of Sports Studies. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

LOCHMANOVÁ Gabriela JEDLIČKOVÁ Lenka POTĚŠIL David TOMANCOVÁ Alexandra VERNER Jan POSPÍŠILOVÁ Šárka DOUBEK Michael MAYER Jiří ZDRÁHAL Zbyněk

Year of publication 2012
Type Article in Periodical
Magazine / Source Proteomics : clinical applications.
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.ncbi.nlm.nih.gov/pubmed/22927351
Doi http://dx.doi.org/10.1002/prca.201100104
Field Oncology and hematology
Keywords BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; C-REACTIVE PROTEIN; SERUM CYTOKINE LEVELS; NECROSIS-FACTOR-ALPHA; ACUTE GVHD; SOLUBLE INTERLEUKIN-2-RECEPTOR; QUANTITATIVE PROTEOMICS; MAJOR COMPLICATIONS; PLASMA BIOMARKERS
Attached files
Description Acute graft-versus-host disease (aGVHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HCT), resulting in considerable morbidity and mortality. Currently, the diagnosis of aGVHD is largely made based on clinical parameters and invasive biopsies. For the past 20 years, researchers have been trying to find reliable biomarkers to enable early and accurate diagnosis of aGVHD. Although a number of potential aGVHD biomarkers have been published, as yet, no validated diagnostic test is available. Proteomics encompasses a broad range of rapidly developing technologies, which have shown tremendous promise for early detection of aGVHD. In this article, we review the current state of aGVHD biomarker discovery, provide a summary of the key proteins of interest and the most common analytical procedures for the clinic, as well as outlining the significant challenges faced in their use.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info